Bio-Rad Laboratories Class A
491 hedge funds and large institutions have $11.2B invested in Bio-Rad Laboratories Class A in 2021 Q1 according to their latest regulatory filings, with 65 funds opening new positions, 203 increasing their positions, 147 reducing their positions, and 61 closing their positions.
61% more call options, than puts
Call options by funds: $22.9M | Put options by funds: $14.2M
38% more repeat investments, than reductions
Existing positions increased: 203 | Existing positions reduced: 147
7% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 61
0% more funds holding
Funds holding: 490 → 491 (+1)
0.27% less ownership
Funds ownership: 79.52% → 79.25% (-0.27%)
2% less capital invested
Capital invested by funds: $11.5B → $11.2B (-$265M)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$118M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$69.1M |
| 3 |
N
Natixis
Paris,
France
|
+$54.7M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$46.9M |
| 5 |
Brown Advisory
Baltimore,
Maryland
|
+$33.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
-$149M |
| 2 |
ACM
Atlanta Capital Management
Atlanta,
Georgia
|
-$141M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$89.9M |
| 4 |
HM
HealthCor Management
New York
|
-$81.7M |
| 5 |
UBS AM
Chicago,
Illinois
|
-$71.5M |
BIO Hedge Fund Activity: Q1 2021 in Review
491 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q1 2021, worth a combined $11.2B — down 2.3% from $11.5B a quarter earlier.
Buyers outnumbered sellers: 65 funds opened new BIO positions and 61 closed out — a net gain of 4 holders — while 203 added to existing stakes and 147 trimmed.
The largest buyer was Marshall Wace, adding an estimated $118M. The largest seller was First Trust Advisors, cutting an estimated $149M.
- 491 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q1 2021, up from 490 in Q4 2020.
- Funds reported $11.2B of Bio-Rad Laboratories Class A stock for Q1 2021, down 2.3% quarter-over-quarter.
- 65 funds opened new Bio-Rad Laboratories Class A positions in Q1 2021 and 61 closed out, a net change of +4 holders.
- The largest Bio-Rad Laboratories Class A buyer in Q1 2021 was Marshall Wace, an estimated $118M added.
- The largest Bio-Rad Laboratories Class A seller in Q1 2021 was First Trust Advisors, an estimated $149M sold.
Based on aggregated 13F filings for Q1 2021.